Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial
- PMID: 22913492
- PMCID: PMC3493260
- DOI: 10.1186/1745-6215-13-144
Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial
Abstract
Background: Hepatocellular carcinoma is a primary malignant tumor of the liver that accounts for an important health problem worldwide. Only 10 to 15% of hepatocellular carcinoma patients are suitable candidates for treatment with curative intent, such as hepatic resection and liver transplantation. A majority of patients have locally advanced, liver restricted disease (Barcelona Clinic Liver Cancer (BCLC) staging system intermediate stage). Transarterial loco regional treatment modalities offer palliative treatment options for these patients; transarterial chemoembolization (TACE) is the current standard treatment. During TACE, a catheter is advanced into the branches of the hepatic artery supplying the tumor, and a combination of embolic material and chemotherapeutics is delivered through the catheter directly into the tumor. Yttrium-90 radioembolization ((90)Y-RE) involves the transarterial administration of minimally embolic microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor. (90)Y-RE is increasingly used in clinical practice for treatment of intermediate stage hepatocellular carcinoma, but its efficacy has never been prospectively compared to that of the standard treatment (TACE). In this study, we describe the protocol of a multicenter randomized controlled trial aimed at comparing the effectiveness of TACE and (90)Y-RE for treatment of patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma.
Methods/design: In this pragmatic randomized controlled trial, 140 patients with unresectable (BCLC intermediate stage) hepatocellular carcinoma, with Eastern Cooperative Oncology Group performance status 0 to 1 and Child-Pugh A to B will be randomly assigned to either (90)Y-RE or TACE with drug eluting beads. Patients assigned to (90)Y-RE will first receive a diagnostic angiography, followed by the actual transarterial treatment, which can be divided into two sessions in case of bilobar disease. Patients assigned to TACE will receive a maximum of three consecutive transarterial treatment sessions. Patients will undergo structural follow-up for a timeframe of two years post treatment. Post procedural magnetic resonance imaging (MRI) will be performed at one and three months post trial entry and at three-monthly intervals thereafter for two years to assess tumor response. Primary outcome will be time to progression. Secondary outcomes will be overall survival, tumor response according to the modified RECIST criteria, toxicities/adverse events, treatment related effect on total liver function, quality of life, treatment-related costs and cost-effectiveness.
Trial registration: NCT01381211.
Similar articles
-
Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.J Hepatol. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025. Epub 2013 May 23. J Hepatol. 2013. PMID: 23707371 Clinical Trial.
-
Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.J Vasc Interv Radiol. 2016 Aug;27(8):1123-9. doi: 10.1016/j.jvir.2016.03.046. Epub 2016 Jun 16. J Vasc Interv Radiol. 2016. PMID: 27321889
-
Transarterial chemoembolization and radioembolization.Semin Liver Dis. 2014 Nov;34(4):435-43. doi: 10.1055/s-0034-1394142. Epub 2014 Nov 4. Semin Liver Dis. 2014. PMID: 25369305 Review.
-
Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.J Vasc Interv Radiol. 2014 Jul;25(7):1075-84. doi: 10.1016/j.jvir.2014.04.014. Epub 2014 May 24. J Vasc Interv Radiol. 2014. PMID: 24861664 Review.
-
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.Trials. 2014 Dec 3;15:474. doi: 10.1186/1745-6215-15-474. Trials. 2014. PMID: 25472660 Free PMC article. Clinical Trial.
Cited by
-
A Pilot Study on Hepatobiliary Scintigraphy to Monitor Regional Liver Function in 90Y Radioembolization.J Nucl Med. 2019 Oct;60(10):1430-1436. doi: 10.2967/jnumed.118.224394. Epub 2019 Apr 6. J Nucl Med. 2019. PMID: 30954942 Free PMC article.
-
Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer.Hepat Oncol. 2014 Apr;1(2):215-228. doi: 10.2217/hep.13.21. Epub 2014 Mar 20. Hepat Oncol. 2014. PMID: 30190956 Free PMC article. Review.
-
Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.Gastroenterol Hepatol (N Y). 2017 Jul;13(7):398-410. Gastroenterol Hepatol (N Y). 2017. PMID: 28867968 Free PMC article.
-
Update on Embolization Therapies for Hepatocellular Carcinoma.Curr Oncol Rep. 2017 Jun;19(6):40. doi: 10.1007/s11912-017-0597-2. Curr Oncol Rep. 2017. PMID: 28421483 Review.
-
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD011649. doi: 10.1002/14651858.CD011649.pub2. Cochrane Database Syst Rev. 2017. PMID: 28281295 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous